Literature DB >> 15330155

Artemisinin: an alternative treatment for oral squamous cell carcinoma.

Eiki Yamachika1, Temesgen Habte, Dolphine Oda.   

Abstract

Artemisinin (AR) is a widely used antimalarial drug. Recently, additional uses for AR as an anticancer drug were discovered. Using TUNEL, immunohistochemistry (IHS) markers and flow cytometry techniques, we evaluated the effect of AR and 5-FU on HPV 16 immortalized and transformed human gingival epithelial (IHGK) cells. The results of TUNEL showed that AR-treated IHGK cells consisted of 82% positive cells, while 5-FU-treated cells consisted of 18% positive cells. The IHS markers demonstrated positive staining with Bax p53, CD40 and CD40L in AR-treated cells and negative staining with Bcl-2. 5-FU-treated cells demonstrated a profile similar to AR but with less intensity. Cell cycle by flow cytometry results showed that only 5-FU-treated cells demonstrated a significant S-phase rate increase to 45%. In conclusion, our results indicate that AR is cytotoxic to transformed oral epithelial cells through apoptosis, while 5-FU is cytotoxic primarily through cell toxicity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15330155

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

Review 1.  Development of artemisinin compounds for cancer treatment.

Authors:  Henry C Lai; Narendra P Singh; Tomikazu Sasaki
Journal:  Invest New Drugs       Date:  2012-08-31       Impact factor: 3.850

2.  Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression.

Authors:  Jamin A Willoughby; Shyam N Sundar; Mark Cheung; Antony S Tin; Jaime Modiano; Gary L Firestone
Journal:  J Biol Chem       Date:  2008-11-17       Impact factor: 5.157

3.  Involvement of Nrf2-mediated upregulation of heme oxygenase-1 in mollugin-induced growth inhibition and apoptosis in human oral cancer cells.

Authors:  Young-Man Lee; Q-Schick Auh; Deok-Won Lee; Jun-Yeol Kim; Ha-Jin Jung; Seung-Ho Lee; Eun-Cheol Kim
Journal:  Biomed Res Int       Date:  2013-05-02       Impact factor: 3.411

4.  Isocudraxanthone K induces growth inhibition and apoptosis in oral cancer cells via hypoxia inducible factor-1α.

Authors:  Mee-Ran Shin; Hwa-Jeong Lee; Soo-Kyung Kang; Q-Schick Auh; Young-Man Lee; Youn-Chul Kim; Eun-Cheol Kim
Journal:  Biomed Res Int       Date:  2014-07-03       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.